Investor Relations

The Global Leader in Bioimpedance Spectroscopy Technology

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedence spectroscopy (BIS) technology to generate powerful data to maximise patient health.

Growth through SOZO SaaS Subscription-based Model

ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.

SOZO® Business Performance

Q3 FY’21

$2.1m

SOZO REVENUE
+50%
YOY^

$8.2m

ARRi
+49%
YOY

$14.5m

CRPii
+20%
YOY

32,000+

PATIENT TESTS
+58%
YOY

90%+

SaaS GROSS MARGINS

1%

CHURN RATE
100% Renewal Rate

^ YOY denotes Year-over-Year change in metric.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCViii that are yet to be reported as recognised revenue.
iii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.

All FY’21 revenue and cash flow numbers are unaudited.
ARR, CRP and TCV are unaudited, non-AASB financial metrics that do not represent revenue in accordance with Australian Accounting Standards. The values shown for total ARR and CRP across all lines of business, including the Core Business and Clinical Business.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Market Performance

Investor Video Call Q3'21

YUHDops3yVQ

Investor Presentation Oct-20

YUHDops3yVQ

Annual Report 2020

Latest ASX Announcements

Analyst coverage

ImpediMed has market-leading coverage with the following entities:

Canaccord Genuity Morgans Wilsons

Share register

ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.

Share register agent

To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:

linkmarketservices.com.au

Ph: 1300-554-474
Fax: +61-2-9287-0303

Locked Bag A14
Sydney South
NSW 1235, Australia

Shareholder services

Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:

InvestorRelations@impedimed.com

ImpediMed maintains an active communications program with investors and the market.

Contact

Investor Relations Contact:

Mike Bassett, Senior Vice President, Corporate and Strategic Development, ImpediMed

+61 4 0743 1432

mbassett@impedimed.com

InvestorRelations@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

+61 3 9866 4722

kwilliamson@we-worldwide.com